Drawing for XIROMED

USPTO serial 86949502

XIROMED

Reviewed by CopyMark Law Group

Reg. 6317944Status 700Renewal
Filing date
Status date
Registration date
Apr 13, 2021
Examiner
HOWARD, PARKER WALDRIP
Law office
GENERIC WEB UPDATE

What this means

This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with XIROMED?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,446*

Plus Government fees of $1,300

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Arturo Perez-Guerrero

Arturo Perez-Guerrero Perez Guerrero LLCP.O. Box 9024163San Juan, PR 00902-4163United States

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparation for use in treating digestive diseases and disorders, gynecological diseases and disorders, hormonal diseases and disorders, blood disorders, cancer, cardiovascular diseases, vascular diseases, gastrointestinal diseases, genitourinary diseases, immunologic diseases, infectious diseases, inflammatory diseases, metabolic diseases and disorders, psychiatric diseases, musculoskeletal system, respiratory system, circulatory system, viral diseases, glaucoma, dental and oral diseases, headaches, migraine, obesity, hepatic treatments, cholesterol, blood pressure and rheumatic treatments; all of the foregoing excluding pharmaceutical preparations for the treatment and/or management of sleep disorders, narcolepsy, cataplexy, and/or excessive daytime sleepiness (EDS); veterinary preparation for treating digestive diseases and disorders, gynecological diseases and disorders, blood disorders, cancer, cardiovascular diseases, vascular diseases, gastrointestinal diseases, genitourinary diseases, immunologic diseases, infectious diseases, inflammatory diseases, metabolic diseases and disorders, musculoskeletal system, respiratory system, circulatory system, viral diseases, glaucoma, dental and oral diseases, headaches, migraine, obesity, hepatic treatments, cholesterol, blood pressure and rheumatic treatments; all of the foregoing excluding pharmaceutical preparations for the treatment and/or management of sleep disorders, narcolepsy, cataplexy, and/or excessive daytime sleepiness (EDS)ACTIVE—
035Sales promotion for others, business management assistance, business management consultancy and market research; presentation of goods by any means of communications for retailing purposes; commercial administration of the licensing of the goods and services of others; organisation of exhibitions, trade fairs or congresses for commercial or advertising purposes; all the aforesaid in this class relating to pharmaceutical businesses and for pharmaceutical preparationsACTIVE—
039Distribution, namely, delivery of pharmaceutical preparations; Transport, packaging and storage services for pharmaceutical preparationsACTIVE—
042Chemical, Biological and Pharmaceutical research services; development of pharmaceutical preparations; clinical trial studies of pharmaceutical preparations for others; evaluation and inspection of pharmaceutical preparationsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 19, 2026APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Oct 9, 2026E15RTEAS SECTION 15 RECEIVED—
Apr 13, 2026REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Jan 9, 2026TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Jan 9, 2026ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 9, 2026REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Sep 14, 2021CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Sep 14, 2021TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Sep 14, 2021ECDRTEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS—
Sep 14, 2021ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 14, 2021REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Sep 14, 2021COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Apr 13, 2021R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Mar 22, 2021AOUMASSIGNMENT OF OWNERSHIP UPDATED MANUALLY—
Mar 5, 2021TMBNTTAB RELEASE CASE TO TRADEMARKS—
Mar 5, 2021OP.TOPPOSITION TERMINATED NO. 999999—
Mar 5, 2021OP.DOPPOSITION DISMISSED NO. 999999—
Jan 16, 2019ASCKASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY—
Oct 9, 2017OP.IOPPOSITION INSTITUTED NO. 999999—
May 11, 2017ETOFEXTENSION OF TIME TO OPPOSE RECEIVED—
Apr 11, 2017NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Apr 11, 2017PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Mar 22, 2017NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Mar 6, 2017PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Mar 1, 2017CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Feb 24, 2017TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Feb 24, 2017CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Feb 13, 2017ERSITEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED—
Feb 3, 2017GNS2NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED—
Feb 3, 2017GNSIINQUIRY TO SUSPENSION E-MAILED—
Feb 3, 2017CNSISUSPENSION INQUIRY WRITTEN—
Jan 27, 2017ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 27, 2017REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Jan 24, 2017RCCKSUSPENSION CHECKED - TO ATTORNEY FOR ACTION—
Jan 23, 2017ALIEASSIGNED TO LIE—
Jul 11, 2016GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Jul 11, 2016GNSLLETTER OF SUSPENSION E-MAILED—
Jul 11, 2016CNSLSUSPENSION LETTER WRITTEN—
Jul 11, 2016XAECEXAMINER'S AMENDMENT ENTERED—
Jul 11, 2016GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Jul 11, 2016GNEAEXAMINERS AMENDMENT E-MAILED—
Jul 11, 2016CNEAEXAMINERS AMENDMENT -WRITTEN—
Jul 6, 2016DOCKASSIGNED TO EXAMINER—
Mar 28, 2016NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Mar 26, 2016NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance